FIRST-TIME-RIGHT DRUG PRODUCT DEVELOPMENT FOR SMALL MOLECULES
Crystal Pharmatech provides integrated formulation development services for oral drug products, helping innovative biotech and pharmaceutical companies accelerate molecules from First-in-Human (FIH) studies to commercial manufacturing. Our First-Time-Right philosophy ensures robust bioavailability, scalable manufacturing, and regulatory readiness from day one.
ELIMINATING DOWNSTREAM RISKS
WHY FIRST-TIME-RIGHT MATTERS
Early shortcuts—such as powder-in-capsule or super placebo approaches—frequently result in costly downstream risks. Our approach eliminates these bottlenecks through integrated design and predictive modeling.
REFORMULATION RISKS
Traditional "fit-for-purpose" strategies often lead to the need for costly reformulation after Proof of Concept (POC).
BIOAVAILABILITY VARIABILITY
Early shortcuts frequently result in bioavailability variability and additional human PK bridging studies with high costs.
REGULATORY & SCALE DELAYS
We ensure scalable processes with a line of sight for late-stage development to prevent regulatory delays.
TAILOR-MADE DESIGN
THE M3 PHILOSOPHY
A well-designed cdmo formulation must balance desired bioavailability, stability, and a scalable manufacturing process. We create tailor-made designs for each molecule.
1. MOLECULE
Target Product Profile (TPP) alignment
Early DMPK and pharmacodynamics assessment
BCS positioning and safety margin integration
2. MATERIAL
Crystal form and solid-state properties
Excipient compatibility and functionality
Mechanical and compaction behavior
3. MEDICINE
Label-driven formulation strategy
Risk-based QbD and CQA/CPP impact analysis
Regulatory-compliant scalability
PROVEN EXPERTISE & COMMITMENT
WHY PARTNER WITH CRYSTAL PHARMATECH?
Combining leadership with deep expertise and state-of-the-art pilot plants to be your trusted partner for IND filings and beyond.
SCIENTIFIC & PROVEN TRACK RECORD
Leadership with average 25+ years MNC experience
Supported 100+ innovative drugs; 15 commercialized
State-of-the-art pilot plants for R&D and manufacturing
CAPABILITY & COMMITMENT
Speed to FIH: "First-Time-Right with Line-of-Sight"
Solubility Enhancement via enabling technologies
Analytical Excellence with validated processes
QUALITY & GLOBAL STANDARDS
cGMP systems meeting NMPA, FDA, and EMA requirements
31 successful global client audits as of January 2026
Cost & Time Optimization via expert recommendations
For more information about cdmo formulation development and contract research pharma, please feel free to contact us!
As a professional cdmo pharma company, crystal biotech trys our best to provide good products and service for you.
Loading comments...